UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-CSR
CERTIFIED SHAREHOLDER REPORT OF REGISTERED
MANAGEMENT INVESTMENT COMPANIES
Investment Company Act File Number: 811-23494
T. Rowe Price Exchange-Traded Funds, Inc.
(Exact name of registrant as specified in charter)
100 East Pratt Street, Baltimore, MD 21202
(Address of principal executive offices)
David Oestreicher
100 East Pratt Street, Baltimore, MD 21202
(Name and address of agent for service)
Registrant’s telephone number, including area code: (410) 345-2000
Date of fiscal year end: October 31
Date of reporting period: April 30, 2024
Item 1. Reports to Shareholders
(a) Report pursuant to Rule 30e-1
![](https://capedge.com/proxy/N-CSRS/0001193125-24-166560/g829230img0cc306061.gif)
T. ROWE PRICE | |
TOUS | International Equity ETF |
For more insights from T. Rowe Price investment professionals, go to troweprice.com. |
![](https://capedge.com/proxy/N-CSRS/0001193125-24-166560/g829230imgbaf06f252.gif)
■ | Timely delivery of important documents |
■ | Convenient access to your documents anytime, anywhere |
■ | Strong security protocols to safeguard sensitive data |
![](https://capedge.com/proxy/N-CSRS/0001193125-24-166560/g829230img7e91243b3.jpg)
![](https://capedge.com/proxy/N-CSRS/0001193125-24-166560/g829230img7b3cf6874.jpg)
Percent of Net Assets | ||
10/31/23 | 4/30/24 | |
Financials | 20.5% | 20.5% |
Industrials and Business Services | 15.9 | 16.6 |
Health Care | 13.6 | 13.6 |
Information Technology | 10.4 | 10.5 |
Consumer Discretionary | 11.2 | 10.0 |
Consumer Staples | 7.9 | 7.3 |
Materials | 6.7 | 6.8 |
Energy | 5.7 | 5.6 |
Communication Services | 4.1 | 4.0 |
Utilities | 2.1 | 2.0 |
Real Estate | 1.4 | 1.6 |
Other and Reserves | 0.5 | 1.5 |
Total | 100.0% | 100.0% |
Percent of Net Assets | |
4/30/24 | |
Novo Nordisk, Denmark | 3.3% |
TotalEnergies, France | 2.8 |
ASML Holding, Netherlands | 2.5 |
Airbus, France | 2.1 |
AstraZeneca, United Kingdom | 2.1 |
Bawag, Austria | 1.7 |
AIA Group, Hong Kong | 1.5 |
SAP, Germany | 1.4 |
Sartorius Stedim Biotech, France | 1.4 |
Unilever, United Kingdom | 1.4 |
Rolls-Royce Holdings, United Kingdom | 1.3 |
Amadeus IT, Spain | 1.2 |
HSBC Holdings, United Kingdom | 1.2 |
Siemens, Germany | 1.2 |
Toyota Motor, Japan | 1.2 |
Experian, United Kingdom | 1.1 |
Hoshizaki, Japan | 1.1 |
AXA, France | 1.0 |
BE Semiconductor Industries, Netherlands | 1.0 |
Galp Energia SGPS, Portugal | 1.0 |
Heineken, Netherlands | 1.0 |
ING Groep, Netherlands | 1.0 |
Roche Holding, Switzerland | 1.0 |
Tokyo Electron, Japan | 1.0 |
UniCredit, Italy | 1.0 |
Total | 36.5% |
Beginning Account Value 11/1/23 | Ending Account Value 4/30/24 | Expenses Paid During Period* 11/1/23 to 4/30/24 | |
Actual | $1,000.00 | $1,183.50 | $2.71 |
Hypothetical (assumes 5% return before expenses) | 1,000.00 | 1,022.38 | 2.51 |
* | Expenses are equal to the fund’s annualized expense ratio for the 6-month period (0.50%), multiplied by the average account value over the period, multiplied by the number of days in the most recent fiscal half year (182), and divided by the days in the year (366) to reflect the half-year period. |
6 Months Ended | 6/14/23 (1) Through | |
4/30/24 | 10/31/23 | |
NET ASSET VALUE | ||
Beginning of period | $ 22.70 | $ 25.00 |
Investment activities | ||
Net investment income(2) (3) | 0.34 | 0.15 |
Net realized and unrealized gain/loss | 3.82 | (2.45) |
Total from investment activities | 4.16 | (2.30) |
Distributions | ||
Net investment income | (0.13) | - |
NET ASSET VALUE | ||
End of period | $ 26.73 | $ 22.70 |
Ratios/Supplemental Data | ||
Total return, based on NAV(3) (4) | 18.35% | (9.20)% |
Ratios to average net assets:(3) | ||
Gross expenses before waivers/payments by Price Associates | 0.50% (5) | 0.50% (5) |
Net expenses after waivers/payments by Price Associates | 0.50% (5) | 0.50% (5) |
Net investment income | 2.61% (5) | 1.60% (5) |
Portfolio turnover rate | 15.7% | 8.9% |
Net assets, end of period (in thousands) | $ 80,196 | $ 61,282 |
(1) | Inception date |
(2) | Per share amounts calculated using average shares outstanding method. |
(3) | Includes the impact of expense-related arrangements with Price Associates. |
(4) | Total return reflects the rate that an investor would have earned on an investment in the fund during period, assuming reinvestment of all distributions. Total return is not annualized for periods less than one year. |
(5) | Annualized |
PORTFOLIO OF INVESTMENTS‡ | Shares | $ Value |
(Cost and value in $000s) | ||
ARGENTINA 0.4% | ||
Common Stocks 0.4% | ||
MercadoLibre (USD) (1) | 214 | 312 |
Total Argentina (Cost $333) | 312 | |
AUSTRALIA 3.4% | ||
Common Stocks 3.4% | ||
BHP Group, Class DI (GBP) | 16,723 | 462 |
Brambles | 34,442 | 324 |
Coles Group | 23,383 | 244 |
Downer EDI | 106,011 | 318 |
National Australia Bank | 19,141 | 415 |
Northern Star Resources | 24,997 | 237 |
Qantas Airways (1) | 38,054 | 143 |
South32 | 123,928 | 283 |
Telstra Group | 75,300 | 178 |
Worley | 9,673 | 93 |
Total Australia (Cost $2,736) | 2,697 | |
AUSTRIA 2.0% | ||
Common Stocks 2.0% | ||
BAWAG Group | 22,924 | 1,369 |
OMV | 4,341 | 206 |
Total Austria (Cost $1,307) | 1,575 | |
CANADA 0.6% | ||
Common Stocks 0.6% | ||
Magna International (USD) (2) | 2,572 | 123 |
Nutrien | 6,952 | 367 |
Total Canada (Cost $560) | 490 |
Shares | $ Value | |
(Cost and value in $000s) | ||
CHINA 0.3% | ||
Common Stocks 0.3% | ||
Alibaba Group Holding, ADR (USD) | 3,032 | 227 |
Total China (Cost $270) | 227 | |
DENMARK 3.5% | ||
Common Stocks 3.5% | ||
Genmab (1) | 454 | 126 |
Novo Nordisk, Class B | 20,838 | 2,672 |
Total Denmark (Cost $1,927) | 2,798 | |
FINLAND 0.4% | ||
Common Stocks 0.4% | ||
Sampo, Class A | 7,238 | 294 |
Total Finland (Cost $292) | 294 | |
FRANCE 15.5% | ||
Common Stocks 15.5% | ||
Airbus | 10,170 | 1,674 |
ArcelorMittal | 16,335 | 408 |
AXA | 23,047 | 796 |
BNP Paribas | 6,104 | 439 |
Dassault Aviation | 1,988 | 426 |
Edenred | 4,331 | 206 |
Engie (1) | 26,833 | 466 |
EssilorLuxottica | 1,870 | 399 |
Eurofins Scientific | 11,624 | 712 |
Euronext | 3,477 | 313 |
Legrand | 3,047 | 313 |
LVMH Moet Hennessy Louis Vuitton | 894 | 734 |
Pluxee (1) | 8,226 | 254 |
Safran | 1,693 | 367 |
Sanofi | 3,692 | 365 |
Sartorius Stedim Biotech | 5,332 | 1,148 |
Shares | $ Value | |
(Cost and value in $000s) | ||
Schneider Electric | 848 | 193 |
SEB | 1,300 | 154 |
Thales | 1,756 | 295 |
TotalEnergies | 31,074 | 2,256 |
Ubisoft Entertainment (1) | 8,745 | 206 |
Vinci | 2,416 | 283 |
Total France (Cost $12,082) | 12,407 | |
GERMANY 7.0% | ||
Common Stocks 7.0% | ||
Allianz | 2,590 | 735 |
BASF | 5,017 | 263 |
Covestro (1) | 6,897 | 345 |
Deutsche Telekom | 28,318 | 649 |
DHL Group | 10,266 | 430 |
E.ON | 19,904 | 264 |
Fresenius SE & KGaA | 3,367 | 100 |
Heidelberg Materials | 4,683 | 471 |
KION Group | 3,042 | 140 |
Mercedes-Benz Group | 2,236 | 169 |
SAP | 6,230 | 1,125 |
Siemens | 5,106 | 957 |
Total Germany (Cost $5,204) | 5,648 | |
HONG KONG 2.9% | ||
Common Stocks 2.9% | ||
AIA Group | 161,600 | 1,183 |
Galaxy Entertainment Group | 86,000 | 386 |
HKT Trust & HKT | 135,000 | 149 |
Hong Kong Exchanges & Clearing | 3,800 | 121 |
Sands China (1) | 72,000 | 170 |
Techtronic Industries | 22,000 | 304 |
Total Hong Kong (Cost $2,881) | 2,313 |
Shares | $ Value | |
(Cost and value in $000s) | ||
HUNGARY 0.4% | ||
Common Stocks 0.4% | ||
OTP Bank | 7,430 | 368 |
Total Hungary (Cost $277) | 368 | |
INDIA 0.3% | ||
Common Stocks 0.3% | ||
ICICI Bank, ADR (USD) | 9,194 | 253 |
Total India (Cost $220) | 253 | |
IRELAND 0.2% | ||
Common Stocks 0.2% | ||
Kingspan Group | 2,270 | 202 |
Total Ireland (Cost $204) | 202 | |
ITALY 4.8% | ||
Common Stocks 4.8% | ||
Davide Campari-Milano | 70,811 | 710 |
Enel | 72,483 | 476 |
Ferrari | 1,526 | 628 |
Intesa Sanpaolo | 175,933 | 659 |
Stellantis | 29,280 | 648 |
UniCredit | 20,799 | 763 |
Total Italy (Cost $3,452) | 3,884 | |
JAPAN 19.3% | ||
Common Stocks 19.3% | ||
Asahi Group Holdings | 12,100 | 414 |
Daiwa Securities Group | 20,100 | 148 |
Fast Retailing | 1,900 | 497 |
Fujitsu | 8,000 | 124 |
Hitachi | 7,500 | 692 |
Hoshizaki | 25,600 | 882 |
Isetan Mitsukoshi Holdings | 12,600 | 177 |
Shares | $ Value | |
(Cost and value in $000s) | ||
Kao | 8,200 | 338 |
Keyence | 1,500 | 660 |
MatsukiyoCocokara | 21,900 | 310 |
Mitsubishi Chemical Group | 47,500 | 277 |
Mitsubishi Electric | 23,300 | 406 |
Mitsubishi Estate | 21,700 | 398 |
Mitsubishi UFJ Financial Group | 59,500 | 593 |
Mitsui | 6,300 | 304 |
Mitsui Fudosan | 58,800 | 598 |
Mizuho Financial Group | 12,500 | 242 |
Murata Manufacturing | 28,600 | 523 |
Nippon Sanso Holdings | 11,900 | 353 |
Nippon Steel | 22,800 | 511 |
Nippon Telegraph & Telephone | 353,900 | 382 |
Nitori Holdings | 1,500 | 201 |
Nomura Real Estate Holdings | 10,100 | 283 |
ORIX | 28,000 | 573 |
Otsuka Holdings | 7,100 | 303 |
Panasonic Holdings | 32,300 | 282 |
Resona Holdings | 40,700 | 257 |
Seven & i Holdings | 18,600 | 240 |
Shionogi | 6,600 | 308 |
Sompo Holdings | 25,800 | 511 |
Sony Group | 3,700 | 306 |
Stanley Electric | 11,100 | 196 |
SUMCO | 19,300 | 288 |
Sumitomo | 17,700 | 465 |
Suntory Beverage & Food | 6,600 | 215 |
Taiheiyo Cement | 7,900 | 181 |
Takeda Pharmaceutical | 11,200 | 294 |
Tokyo Electron | 3,700 | 812 |
Toyota Motor | 40,800 | 931 |
Total Japan (Cost $14,348) | 15,475 |
Shares | $ Value | |
(Cost and value in $000s) | ||
LUXEMBOURG 0.3% | ||
Common Stocks 0.3% | ||
CVC Capital Partners (1) | 13,903 | 252 |
Total Luxembourg (Cost $208) | 252 | |
NETHERLANDS 8.2% | ||
Common Stocks 8.2% | ||
AerCap Holdings (USD) (1) | 3,830 | 324 |
Akzo Nobel | 3,940 | 260 |
ASML Holding | 2,297 | 2,001 |
BE Semiconductor Industries | 6,228 | 826 |
Heineken | 8,118 | 790 |
ING Groep | 51,548 | 815 |
Koninklijke Ahold Delhaize | 5,232 | 159 |
Koninklijke KPN | 72,484 | 263 |
Koninklijke Philips | 16,874 | 448 |
Prosus | 11,272 | 377 |
Universal Music Group | 11,043 | 325 |
Total Netherlands (Cost $6,006) | 6,588 | |
NORWAY 0.2% | ||
Common Stocks 0.2% | ||
Equinor | 6,410 | 171 |
Total Norway (Cost $160) | 171 | |
PORTUGAL 1.1% | ||
Common Stocks 1.1% | ||
Galp Energia SGPS | 35,776 | 768 |
Jeronimo Martins | 5,583 | 115 |
Total Portugal (Cost $635) | 883 | |
SINGAPORE 1.0% | ||
Common Stocks 1.0% | ||
DBS Group Holdings | 12,650 | 322 |
Shares | $ Value | |
(Cost and value in $000s) | ||
United Overseas Bank | 22,593 | 501 |
Total Singapore (Cost $764) | 823 | |
SOUTH KOREA 0.5% | ||
Common Stocks 0.5% | ||
Samsung Electronics | 6,658 | 370 |
Total South Korea (Cost $373) | 370 | |
SPAIN 2.4% | ||
Common Stocks 2.4% | ||
Amadeus IT Group, Class A | 15,270 | 969 |
Banco Santander (2) | 97,849 | 476 |
Iberdrola | 36,902 | 453 |
Total Spain (Cost $1,938) | 1,898 | |
SWEDEN 2.2% | ||
Common Stocks 2.2% | ||
Assa Abloy, Class B | 12,613 | 333 |
Boliden | 5,078 | 167 |
Essity Aktiebolag, Class B | 6,780 | 169 |
Hexagon, Class B | 28,122 | 294 |
Sandvik (2) | 11,885 | 237 |
Swedbank, Class A | 19,283 | 369 |
Telefonaktiebolaget LM Ericsson, Class B | 46,868 | 238 |
Total Sweden (Cost $1,773) | 1,807 | |
SWITZERLAND 3.5% | ||
Common Stocks 3.5% | ||
Julius Baer Group | 3,859 | 207 |
Nestle | 4,764 | 478 |
Novartis | 3,978 | 386 |
Roche Holding | 3,412 | 818 |
Sonova Holding | 1,896 | 524 |
Shares | $ Value | |
(Cost and value in $000s) | ||
Zurich Insurance Group | 849 | 411 |
Total Switzerland (Cost $3,175) | 2,824 | |
TAIWAN 0.8% | ||
Common Stocks 0.8% | ||
Taiwan Semiconductor Manufacturing | 26,000 | 623 |
Total Taiwan (Cost $486) | 623 | |
UNITED KINGDOM 17.3% | ||
Common Stocks 17.3% | ||
3i Group | 7,544 | 270 |
Amcor (AUD) | 12,930 | 115 |
AstraZeneca, ADR (USD) | 22,410 | 1,700 |
Auto Trader Group | 22,976 | 199 |
Barclays | 238,964 | 602 |
BP | 94,002 | 606 |
BT Group | 237,720 | 304 |
Bunzl | 10,371 | 398 |
CRH | 4,920 | 381 |
Endava, ADR (USD) (1) | 16,203 | 470 |
Experian | 21,930 | 884 |
Glencore | 60,021 | 349 |
GSK, ADR (USD) | 15,541 | 644 |
HSBC Holdings | 111,188 | 964 |
Imperial Brands | 28,487 | 651 |
Informa | 33,955 | 336 |
Intermediate Capital Group | 21,460 | 559 |
Next | 1,890 | 212 |
Prudential | 28,622 | 249 |
Rentokil Initial | 74,181 | 374 |
Rolls-Royce Holdings (1) | 205,151 | 1,052 |
Shell | 13,370 | 475 |
Smiths Group | 12,730 | 257 |
Taylor Wimpey | 186,549 | 306 |
Shares | $ Value | |
(Cost and value in $000s) | ||
Unilever | 21,007 | 1,087 |
Wise, Class A (1) | 22,053 | 212 |
WPP | 20,826 | 209 |
Total United Kingdom (Cost $12,994) | 13,865 | |
SHORT-TERM INVESTMENTS 0.9% | ||
Money Market Funds 0.9% | ||
State Street Institutional U.S. Government Money Market Fund, 5.25% (3) | 698,249 | 698 |
Total Short-Term Investments (Cost $698) | 698 | |
SECURITIES LENDING COLLATERAL 0.9% | ||
Investments in a Pooled Account through Securities Lending Program with State Street Bank 0.9% | ||
Money Market Funds 0.9% | ||
T. Rowe Price Government Reserve Fund, 5.37% (3)(4) | 708,204 | 708 |
Total Investments in a Pooled Account through Securities Lending Program with State Street Bank | 708 | |
Total Securities Lending Collateral (Cost $708) | 708 | |
Total Investments 100.3% of Net Assets (Cost $76,011) | $80,453 |
‡ | Country classifications are generally based on MSCI categories or another unaffiliated third party data provider; Shares are denominated in the currency of the country presented unless otherwise noted. |
(1) | Non-income producing. |
(2) | All or a portion of this security is on loan at April 30, 2024. See Note 4. |
(3) | Seven-day yield |
(4) | Affiliated Companies |
ADR | American Depositary Receipts |
AUD | Australian Dollar |
GBP | British Pound |
SEK | Swedish Krona |
USD | U.S. Dollar |
FORWARD CURRENCY EXCHANGE CONTRACTS |
Counterparty | Settlement | Receive | Deliver | Unrealized Gain/(Loss) | ||
State Street Bank London | 5/2/24 | USD | 5 | SEK | 54 | $— |
Net unrealized gain (loss) on open forward currency exchange contracts | $— |
Affiliate | Net Realized Gain (Loss) | Changes in Net Unrealized Gain/Loss | Investment Income |
T. Rowe Price Government Reserve Fund | $ — | $— | $—++ |
Totals | $—# | $— | $ —+ |
Supplementary Investment Schedule | ||||
Affiliate | Value 10/31/23 | Purchase Cost | Sales Cost | Value 4/30/24 |
T. Rowe Price Government Reserve Fund | $ — | ¤ | ¤ | $ 708 |
Total | $708^ |
++ | Excludes earnings on securities lending collateral, which are subject to rebates and fees. |
# | Capital gain distributions from mutual funds represented $0 of the net realized gain (loss). |
+ | Investment income comprised $0 of dividend income and $0 of interest income. |
¤ | Purchase and sale information not shown for cash management funds. |
^ | The cost basis of investments in affiliated companies was $708. |
Assets | |
Investments in securities, at value (cost $76,011) | $80,453 |
Dividends receivable | 381 |
Foreign currency (cost $104) | 103 |
Total assets | 80,937 |
Liabilities | |
Obligation to return securities lending collateral | 708 |
Investment management and administrative fees payable | 33 |
Total liabilities | 741 |
NET ASSETS | $ 80,196 |
Net assets consists of: | |
Total distributable earnings (loss) | $ 4,816 |
Paid-in capital applicable to 3,000,000 shares of $0.0001 par value capital stock outstanding; 4,000,000,000 shares authorized | 75,380 |
NET ASSETS | $80,196 |
NET ASSET VALUE PER SHARE | $ 26.73 |
6 Months Ended | |
4/30/24 | |
Investment Income (Loss) | |
Income | |
Dividend (net of foreign taxes of $118) | $ 1,170 |
Securities lending | 1 |
Total income | 1,171 |
Investment management and administrative expense | 188 |
Net investment income | 983 |
Realized and Unrealized Gain / Loss | |
Net realized gain (loss) | |
Securities | (839) |
In-kind redemptions | 961 |
Forward currency exchange contracts | 1 |
Foreign currency transactions | 4 |
Net realized gain | 127 |
Change in net unrealized gain / loss | |
Securities | 10,730 |
Other assets and liabilities denominated in foreign currencies | (8) |
Change in unrealized gain / loss | 10,722 |
Net realized and unrealized gain / loss | 10,849 |
INCREASE IN NET ASSETS FROM OPERATIONS | $ 11,832 |
6 Months Ended | 6/14/23 Through | ||
4/30/24 | 10/31/23 | ||
Increase (Decrease) in Net Assets | |||
Operations | |||
Net investment income | $ 983 | $ 300 | |
Net realized gain (loss) | 127 | (647) | |
Change in net unrealized gain / loss | 10,722 | (6,288) | |
Increase (decrease) in net assets from operations | 11,832 | (6,635) | |
Distributions to shareholders | |||
Net earnings | (375) | — | |
Capital share transactions* | |||
Shares sold | 11,581 | 69,113 | |
Shares redeemed | (4,124) | (1,196) | |
Increase in net assets from capital share transactions | 7,457 | 67,917 | |
Net Assets | |||
Increase during period | 18,914 | 61,282 | |
Beginning of period | 61,282 | - | |
End of period | $80,196 | $61,282 | |
*Share information | |||
Shares sold | 450 | 2,750 | |
Shares redeemed | (150) | (50) | |
Increase in shares outstanding | 300 | 2,700 |
($000s) | Level 1 | Level 2 | Level 3 | Total Value |
Assets | ||||
Common Stocks | $4,053 | $74,994 | $— | $79,047 |
Short-Term Investments | 698 | — | — | 698 |
Securities Lending Collateral | 708 | — | — | 708 |
Total | $5,459 | $74,994 | $— | $80,453 |
($000s) | Location of Gain (Loss) on Statement of Operations |
Forward Currency Exchange Contracts | |
Realized Gain (Loss) | |
Foreign exchange derivatives | $1 |
![](https://capedge.com/proxy/N-CSRS/0001193125-24-166560/g829230img363d35365.gif)
Item 1. (b) Notice pursuant to Rule 30e-3.
Not applicable.
Item 2. Code of Ethics.
A code of ethics, as defined in Item 2 of Form N-CSR, applicable to its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions is filed as an exhibit to the registrant’s annual Form N-CSR. No substantive amendments were approved or waivers were granted to this code of ethics during the registrant’s most recent fiscal half-year.
Item 3. Audit Committee Financial Expert.
Disclosure required in registrant’s annual Form N-CSR.
Item 4. Principal Accountant Fees and Services.
Disclosure required in registrant’s annual Form N-CSR.
Item 5. Audit Committee of Listed Registrants.
Not applicable.
Item 6. Investments.
(a) Not applicable. The complete schedule of investments is included in Item 1 of this Form N-CSR.
(b) Not applicable.
Item 7. Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.
Not applicable.
Item 8. Portfolio Managers of Closed-End Management Investment Companies.
Not applicable.
Item 9. Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.
Not applicable.
Item 10. Submission of Matters to a Vote of Security Holders.
There has been no change to the procedures by which shareholders may recommend nominees to the registrant’s board of directors.
Item 11. Controls and Procedures.
(a) The registrant’s principal executive officer and principal financial officer have evaluated the registrant’s disclosure controls and procedures within 90 days of this filing and have concluded that the registrant’s disclosure controls and procedures were effective, as of that date, in ensuring that information required to be disclosed by the registrant in this Form N-CSR was recorded, processed, summarized, and reported timely.
(b) The registrant’s principal executive officer and principal financial officer are aware of no change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
Item 12. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.
Not applicable.
Item 13. Exhibits.
(a)(1) | The registrant’s code of ethics pursuant to Item 2 of Form N-CSR is filed with the registrant’s annual Form N-CSR. | |
(2) | ||
(3) | Written solicitation to repurchase securities issued by closed-end companies: not applicable. | |
(b) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
T. Rowe Price Exchange-Traded Funds, Inc. | ||||
By | /s/ David Oestreicher | |||
David Oestreicher | ||||
Principal Executive Officer | ||||
Date | June 17, 2024 |
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
By | /s/ David Oestreicher | |||
David Oestreicher | ||||
Principal Executive Officer | ||||
Date | June 17, 2024 |
By | /s/ Alan S. Dupski | |||
Alan S. Dupski | ||||
Principal Financial Officer | ||||
Date | June 17, 2024 |